US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Evolus, Inc. - Common Stock (NQ:EOLS)

7.350 -0.170 (-2.26%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Evolus to Participate in Upcoming Investor Conferences in New York and London
From Evolus
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Evolus to Report Third Quarter Financial Results on November 4, 2026
From Evolus
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
From Pomerantz LLP
Via GlobeNewswire
Evolus Inc (NASDAQ:EOLS) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7% ↗
Via Chartmill
Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally ↗
Via Chartmill
News headline image
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
From Evolus, Inc.
Via Business Wire
News headline image
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
From Evolus
Via Business Wire
News headline image
Telix Appoints David Gill as Chair
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus Q2 Earnings Call Highlights ↗
Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid... 
Via MarketBeat
Topics Earnings
News headline image
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
From Evolus
Via Business Wire
News headline image
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
From Evolus
Via Business Wire
News headline image
Evolus to Report Second Quarter Financial Results on August 5, 2026
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
From Evolus
Via Business Wire
News headline image
Evolus to Participate in The Jefferies Global Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
From Evolus
Via Business Wire
News headline image
Evolus (EOLS) Q1 2026 Earnings Transcript ↗
Evolus (EOLS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics World Trade
News headline image
Evolus (EOLS) Q2 2025 Earnings Call Transcript ↗
Evolus (EOLS) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
From Evolus
Via Business Wire
News headline image
Evolus to Report First Quarter Financial Results on May 4, 2026
From Evolus
Via Business Wire
News headline image
Telix Appoints David Gill as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Why Evolus Stock Soared Today ↗
The promise of a more youthful appearance is a powerful draw. 
Via The Motley Fool
What's going on in today's session ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >